Pharmaco - Press Releases

Date	Title	Company
23-Mar-2023	Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial	Sanofi
23-Mar-2023	PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million	PureTech Health
23-Mar-2023	InvoX Pharma’s F-star announces licence agreement with Takeda for second novel next-generation immuno-oncology bispecific antibody	InvoX Pharma Limited
23-Mar-2023	Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO	Tiziana Life Sciences
23-Mar-2023	Envirotainer sees improvements in access to biopharmaceuticals across the globe	Envirotainer
23-Mar-2023	Original-Research: Haemato AG (von First Berlin Equity Research GmbH)	Haemato AG
23-Mar-2023	MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)	MorphoSys AG
23-Mar-2023	Connect in Pharma releases report on future trends in pharma production and manufacturing	Sciad Newswire
23-Mar-2023	Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance	Cosmo Pharmaceuticals N.V.
23-Mar-2023	Zur Rose Group: Revenue and earnings targets for 2022 achieved; significant step towards profitability	Zur Rose Group AG
23-Mar-2023	Biotest AG: Biotest core business profitable at Euro 60.7 million	Biotest AG
22-Mar-2023	Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression	Dewpoint Therapeutics
22-Mar-2023	Sernova: Abstract on First Cohort of its Phase 1/2 Study Involving Islet Transplantation into Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions	Sernova Corp.
22-Mar-2023	Dermapharm Holding SE: 2022 dividend	Dermapharm Holding SE
22-Mar-2023	KITE’S YESCARTA® (AXICABTAGENE CILOLEUCEL) CAR T-CELL THERAPY DEMONSTRATES A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL FOR INITIAL TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)	Kite
22-Mar-2023	Aptamer launches Optimer®-Fc as a new reagent solution for immunohistochemistry	Aptamer Group plc
22-Mar-2023	Global pharmaceutical company moves into life sciences hub White City Place	invoX Pharma Ltd
22-Mar-2023	Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis	Sanofi
22-Mar-2023	Douglas GmbH: DOUGLAS accelerates growth with strict customer focus and targeted omni-channel set-up	Douglas GmbH
22-Mar-2023	Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™	Cosmo Pharmaceuticals N.V.